{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:47:58Z","timestamp":1783784878629,"version":"3.55.0"},"reference-count":141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T00:00:00Z","timestamp":1592006400000},"content-version":"am","delay-in-days":286,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.critrevonc.2019.05.015","type":"journal-article","created":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T22:42:26Z","timestamp":1559256146000},"page":"23-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6031-4816","authenticated-orcid":false,"given":"Arnaud","family":"Jannin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5243-1548","authenticated-orcid":false,"given":"Nicolas","family":"Penel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Ladsous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Christine","family":"Vantyghem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Do Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2019.05.015_bib0005","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1586\/14737140.2014.929501","article-title":"Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis","volume":"14","author":"Abdel-Rahman","year":"2014","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0010","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1210\/jc.2009-2507","article-title":"Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination","volume":"95","author":"Abdulrahman","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0015","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/jjco\/hyv045","article-title":"Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients","volume":"45","author":"Akaza","year":"2015","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0020","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.gendis.2017.11.002","article-title":"Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma","volume":"5","author":"Angell","year":"2018","journal-title":"Genes Dis."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0025","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","article-title":"Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0030","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0035","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1124\/jpet.105.084145","article-title":"Role of tyrosine kinase inhibitors in cancer therapy","volume":"315","author":"Arora","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0040","first-page":"2087525","article-title":"Treatment of Ipilimumab Induced Graves\u2019 Disease in a Patient with Metastatic Melanoma","author":"Azmat","year":"2016","journal-title":"Case Rep. Endocrinol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0050","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0055","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/cncr.31200","article-title":"Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management","volume":"124","author":"Barroso-Sousa","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European Thyroid Association\/European group on graves\u2019 orbitopathy guidelines for the management of graves\u2019 orbitopathy","volume":"5","author":"Bartalena","year":"2016","journal-title":"Eur. Thyroid J."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0065","unstructured":"BAVENCIO\u00ae (avelumab), prescribing information, 2017."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0070","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0075","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1210\/jc.2016-4025","article-title":"Sorafenib-induced changes in thyroid hormone levels in patients treated for hepatocellular carcinoma","volume":"102","author":"Beukhof","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0080","doi-asserted-by":"crossref","first-page":"R233","DOI":"10.1530\/ERC-13-0201","article-title":"Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma","volume":"20","author":"Bianchi","year":"2013","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0085","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0090","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/IOP.0b013e3181ef72a1","article-title":"Drug-induced graves disease from CTLA-4 receptor suppression","volume":"27","author":"Borodic","year":"2011","journal-title":"Ophthal. Plast. Reconstr. Surg."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0095","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0100","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0105","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0110","doi-asserted-by":"crossref","first-page":"E100","DOI":"10.1210\/jc.2011-1837","article-title":"Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport","volume":"97","author":"Braun","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"49","key":"10.1016\/j.critrevonc.2019.05.015_bib0115","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1016\/j.ejca.2013.05.028","article-title":"Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study","volume":"1990","author":"Bruix","year":"2013","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0120","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nrendo.2014.114","article-title":"VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs","volume":"10","author":"Cao","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0125","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"94","key":"10.1016\/j.critrevonc.2019.05.015_bib0130","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2018.02.012","article-title":"Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update","volume":"1990","author":"Choueiri","year":"2018","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0135","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.16145","article-title":"Thyroid dysfunction in patients (pts) with metastatic renal cell cancer (RCC) treated with sorafenib [abstract 16145]","author":"Clement","year":"2008","journal-title":"American Society of Clinical Oncology 44th Annual Meeting (ASCO)"},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0140","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1590\/S1677-5538.IBJU.2015.0226","article-title":"Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer institute (INCA) experience","volume":"42","author":"Coelho","year":"2016","journal-title":"Int. Braz J Urol Off. J. Braz. Soc. Urol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0145","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jjco\/hys076","article-title":"Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma","volume":"42","author":"Daimon","year":"2012","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0150","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/imr.12349","article-title":"Human IgG4: a structural perspective","volume":"268","author":"Davies","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0155","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","author":"de Filette","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0160","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clpt.2005.06.010","article-title":"Imatinib induces hypothyroidism in patients receiving levothyroxine","volume":"78","author":"de Groot","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0165","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1210\/jc.2007-0649","article-title":"A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma","volume":"92","author":"de Groot","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0170","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms","volume":"102","author":"Delivanis","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0175","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-145-9-200611070-00008","article-title":"Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors","volume":"145","author":"Desai","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0180","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1200\/JCO.2006.09.0803","article-title":"Economics of new oncology drug development","volume":"25","author":"DiMasi","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ando.2018.07.003","article-title":"Expert opinion on thyroid complications of new anti-cancer therapies: tyrosine kinase inhibitors","author":"Drui","year":"2018","journal-title":"Ann. Endocrinol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0190","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0195","first-page":"16","article-title":"Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma","author":"Eroukhmanoff","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0200","first-page":"723","article-title":"Thyroid dysfunctions induced by tyrosine kinase inhibitors","volume":"13","author":"Fallahi","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0205","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0210","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0215","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3109\/0284186X.2012.752579","article-title":"Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis","volume":"52","author":"Funakoshi","year":"2013","journal-title":"Acta Oncol. Stockh. Swed."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0220","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000464285","article-title":"Tremelimumab-induced graves hyperthyroidism","volume":"6","author":"Gan","year":"2017","journal-title":"Eur. Thyroid J."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0225","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0230","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrclinonc.2015.213","article-title":"Kinase inhibitors and monoclonal antibodies in oncology: clinical implications","volume":"13","author":"Gharwan","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0235","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":"Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial","volume":"10","author":"Gore","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0240","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1470-2045(17)30240-1","article-title":"Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial","volume":"18","author":"Gulley","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0245","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.humimm.2006.05.003","article-title":"CTLA4 Polymorphisms and Ophthalmopathy in Graves\u2019 Disease Patients: Association Study and Meta-Analysis","volume":"67","author":"Han","year":"2006","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0250","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0255","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1210\/jcem.87.7.8678","article-title":"Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies","volume":"87","author":"Huber","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0260","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S1470-2045(13)70465-0","article-title":"Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial","volume":"14","author":"Hutson","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0265","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s00535-016-1263-4","article-title":"Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma","volume":"52","author":"Ikeda","year":"2017","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.ando.2018.07.007","article-title":"Expert opinion on thyroid complications in immunotherapy","author":"Illouz","year":"2018","journal-title":"Ann. Endocrinol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0275","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1530\/EJE-08-0648","article-title":"Tyrosine kinase inhibitors and modifications of thyroid function tests: a review","volume":"160","author":"Illouz","year":"2009","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0280","unstructured":"IMFINZITM (durvalumab), prescribing information, 2017."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0285","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1507\/endocrj1954.35.447","article-title":"Increase in peripheral large granular lymphocytes in postpartum autoimmune thyroiditis","volume":"35","author":"Iwatani","year":"1988","journal-title":"Endocrinol. Jpn."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0290","doi-asserted-by":"crossref","first-page":"R196","DOI":"10.1530\/EC-18-0079","article-title":"Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism","volume":"7","author":"Jaafar","year":"2018","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0295","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jaut.2007.11.010","article-title":"The HLA gene complex in thyroid autoimmunity: from epidemiology to etiology","volume":"30","author":"Jacobson","year":"2008","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0300","doi-asserted-by":"crossref","first-page":"750","DOI":"10.15252\/emmm.201607341","article-title":"VEGFR2 but not VEGFR3 governs integrity and remodeling of thyroid angiofollicular unit in normal state and during goitrogenesis","volume":"9","author":"Jang","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0305","doi-asserted-by":"crossref","first-page":"H560","DOI":"10.1152\/ajpheart.00133.2005","article-title":"VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature","volume":"290","author":"Kamba","year":"2006","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0310","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1210\/jc.2011-1172","article-title":"Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression","volume":"96","author":"Kappers","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0315","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.eururo.2014.01.035","article-title":"Phase II Trial Of Neoadjuvant Axitinib In Patients With Locally Advanced Non-Metastatic Clear Cell Renal Cell Carcinoma","volume":"66","author":"Karam","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0320","first-page":"896","article-title":"Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland","volume":"48","author":"Karantanis","year":"2007","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0325","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40425-017-0213-x","article-title":"Nivolumab induced myxedema crisis","volume":"5","author":"Khan","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0330","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1089\/thy.2010.0251","article-title":"Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia","volume":"20","author":"Kim","year":"2010","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0335","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.ejrad.2011.06.035","article-title":"Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function","volume":"81","author":"Kitajima","year":"2012","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0340","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1210\/js.2017-00432","article-title":"Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0345","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1007\/s12020-012-9683-2","article-title":"Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer","volume":"42","author":"Konca Degertekin","year":"2012","journal-title":"Endocrine"},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0350","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000485972","article-title":"Lenvatinib for anaplastic thyroid cancer and lenvatinib-induced thyroid dysfunction","volume":"7","author":"Koyama","year":"2018","journal-title":"Eur. Thyroid J."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0355","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJMra044389","article-title":"Tyrosine kinases as targets for cancer therapy","volume":"353","author":"Krause","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0360","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0365","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0370","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/thy.2017.0579","article-title":"Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients","volume":"28","author":"Lechner","year":"2018","journal-title":"Thyroid"},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0375","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1089\/thy.2014.0006","article-title":"Sunitinib does not block thyroid peroxidase in patients","volume":"24","author":"Liwanpo","year":"2014","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0380","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1687-9856-2015-3","article-title":"Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy","author":"Lodish","year":"2015","journal-title":"Int. J. Pediatr. Endocrinol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0385","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/thy.2012.0456","article-title":"Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis","volume":"23","author":"Makita","year":"2013","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0390","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1089\/thy.2009.0414","article-title":"Sunitinib induces hypothyroidism with a markedly reduced vascularity","volume":"20","author":"Makita","year":"2010","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0395","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1210\/jc.2007-0586","article-title":"A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake","volume":"92","author":"Mannavola","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"49","key":"10.1016\/j.critrevonc.2019.05.015_bib0400","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1016\/j.ejca.2013.06.003","article-title":"Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies","volume":"1990","author":"Matrana","year":"2013","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0405","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1093\/annonc\/mdt291","article-title":"Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)","volume":"24","author":"McDermott","year":"2013","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0410","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-214603","article-title":"A rare case of thyroid storm","author":"McMillen","year":"2016","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0415","doi-asserted-by":"crossref","first-page":"14034","DOI":"10.1073\/pnas.0806584105","article-title":"Molecular amino acid signatures in the MHC class II peptide-binding pocket predispose to autoimmune thyroiditis in humans and in mice","volume":"105","author":"Menconi","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0420","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.urolonc.2009.08.011","article-title":"Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation","volume":"28","author":"Miyake","year":"2010","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0425","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/cen.13297","article-title":"Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma","volume":"86","author":"Morganstein","year":"2017","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0430","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","article-title":"Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0435","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0440","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0445","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2011.36.4133","article-title":"Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma","volume":"30","author":"Motzer","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0450","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/j.1349-7006.2009.01465.x","article-title":"Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients","volume":"101","author":"Mukohara","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0455","doi-asserted-by":"crossref","first-page":"574","DOI":"10.4103\/2230-8210.137524","article-title":"Immunoregulatory T cells, LFA-3 and HLA-DR in autoimmune thyroid diseases","volume":"18","author":"Nada","year":"2014","journal-title":"Indian J. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0460","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1089\/thy.2012.0378","article-title":"Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib","volume":"23","author":"Ohba","year":"2013","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0465","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1210\/jc.2014-4560","article-title":"Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies","volume":"100","author":"Orlov","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0470","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0475","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1158\/0008-5472.CAN-08-4709","article-title":"The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies","volume":"69","author":"Ozao-Choy","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0480","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1089\/thy.2015.0170","article-title":"Thyroid dysfunction in patients with metastatic carcinoma treated with sunitinib: is thyroid autoimmunity involved?","volume":"25","author":"Pani","year":"2015","journal-title":"Thyroid off. J. Am. Thyroid Assoc."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0485","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1530\/EJE-17-0231","article-title":"Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link?","volume":"177","author":"Pani","year":"2017","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0490","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1200\/JCO.2016.71.9476","article-title":"Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)","volume":"35","author":"Peters","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0495","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.eururo.2015.07.006","article-title":"Long-term safety of sunitinib in metastatic renal cell carcinoma","volume":"69","author":"Porta","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0500","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0505","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1\/2 Open-label Study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0510","article-title":"Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma: Real-world Data From an Italian Managed Access Program","author":"Prisciandaro","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0515","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1634\/theoncologist.2017-0552","article-title":"Cabozantinib in patients with advanced merkel cell carcinoma","volume":"23","author":"Rabinowits","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0520","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0525","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0530","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00345-010-0627-2","article-title":"Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib","volume":"29","author":"Riesenbeck","year":"2011","journal-title":"World J. Urol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0535","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1200\/JCO.2007.15.5416","article-title":"Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma","volume":"26","author":"Rini","year":"2008","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0540","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jnci\/djk008","article-title":"Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"99","author":"Rini","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0545","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0550","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1210\/jc.2009-2461","article-title":"Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"95","author":"Robinson","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0555","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/annonc\/mdr275","article-title":"Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?","volume":"23","author":"Sabatier","year":"2012","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0560","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1089\/thy.2007.0336","article-title":"Effect of sunitinib on growth and function of FRTL-5 thyroid cells","volume":"18","author":"Salem","year":"2008","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0565","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1507\/endocrj.K10E-130","article-title":"Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma","volume":"57","author":"Sato","year":"2010","journal-title":"Endocr. J."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0570","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/annonc\/mdx479","article-title":"Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma","volume":"28","author":"Schlumberger","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0575","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1078-0432.CCR-15-1127","article-title":"A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid Cancer","volume":"22","author":"Schlumberger","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0580","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cncr.25422","article-title":"Hypothyroidism in patients with renal cell carcinoma: blessing or curse?","volume":"117","author":"Schmidinger","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0585","series-title":"Sunitinib-related Thyroid Dysfunction: A Single-center Retrospective and Prospective Evaluation [WWW Document]","author":"Schoeffski","year":"2006"},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0590","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.bjc.6606029","article-title":"The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma","volume":"104","author":"Shinohara","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0595","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147048","article-title":"Hypothyroidism side effect in patients treated with sunitinib or sorafenib: clinical and structural analyses","volume":"11","author":"Shu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0600","first-page":"975","article-title":"Hypoxia-inducible factor induces local thyroid hormone inactivation during hypoxic-ischemic disease in rats","volume":"118","author":"Simonides","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0605","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0610","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/annonc\/mdm483","article-title":"Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib","volume":"19","author":"Tamaskar","year":"2008","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0615","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrendo.2018.18","article-title":"Global epidemiology of hyperthyroidism and hypothyroidism","volume":"14","author":"Taylor","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0620","unstructured":"TECENTRIQ\u00ae(atezolizumab), prescribing information., n.d."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0625","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1089\/thy.2010.1644","article-title":"Genetic Susceptibility to Autoimmune Thyroid Disease: Past, Present, and Future","volume":"20","author":"Tomer","year":"2010","journal-title":"Thyroid"},{"issue":"47","key":"10.1016\/j.critrevonc.2019.05.015_bib0630","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1016\/j.ejca.2011.07.014","article-title":"Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma","volume":"1990","author":"Tomita","year":"2011","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0635","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0640","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrclinonc.2009.4","article-title":"Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy","volume":"6","author":"Torino","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0645","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/jjco\/hyt054","article-title":"Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial","volume":"43","author":"Ueda","year":"2013","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0650","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1089\/thy.2013.0147","article-title":"Reduction in thyroid perfusion after bevacizumab treatment","volume":"23","author":"van der Veldt","year":"2013","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0655","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/cen.13483","article-title":"Endocrinopathies with use of cancer immunotherapies","volume":"88","author":"Villa","year":"2018","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0660","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0665","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0670","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0675","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/sj.bjc.6604497","article-title":"The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation","volume":"99","author":"Wolter","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0680","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/thy.2006.0308","article-title":"Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity","volume":"17","author":"Wong","year":"2007","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0685","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1158\/1078-0432.CCR-10-2638","article-title":"Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors","volume":"17","author":"Yamada","year":"2011","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0690","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1089\/thy.2016.0562","article-title":"Clinical features of nivolumab-induced thyroiditis: a case series study","volume":"27","author":"Yamauchi","year":"2017","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0695","doi-asserted-by":"crossref","first-page":"12018","DOI":"10.1073\/pnas.1301331110","article-title":"Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues","volume":"110","author":"Yang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0700","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1089\/thy.2013.0621","article-title":"Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma","volume":"24","author":"Yavuz","year":"2014","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"key":"10.1016\/j.critrevonc.2019.05.015_bib0705","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1210\/jcem-46-6-859","article-title":"Association of serum antithyroid antibodies with lymphocytic infiltration of the thyroid gland: studies of seventy autopsied cases","volume":"46","author":"Yoshida","year":"1978","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842819301076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842819301076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:31:14Z","timestamp":1760902274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842819301076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":141,"alternative-id":["S1040842819301076"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.05.015","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}